On July 17, Astellas Pharma announced that it had entered into an agreement with Frequency Therapeutics to co-develop and commercialise FX-322, a regenerative therapy to treat hearing loss.

Feb. 13 (UPI) --Regenerative medicine company Frequency Therapeutics announced Monday it will scrap development of a drug called FX-322, after testing failed to show improvement in speech ...

A pending reverse merger with troubled Frequency Therapeutics is giving new meaning to Korro Bio’s slogan, “Edit the message. Rewrite the future.” For Korro, a developer of RNA-edited ...

FREQ Frequency Therapeutics Inc Korro Bio and Frequency Therapeutics Announce Merger Agreement Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio's wholly ...

Image source: Prostock-studio / Adobe Frequency Therapeutics, an MIT spinout, is looking for new ways to reverse hearing loss. Not by equipping patients with hearing aids or implants, though.

Still, as a publicly traded company, Frequency Therapeutics, which described the negative results as "unexpected," saw its share prices plummet in the weeks that followed. Shares had peaked at $54 ...

Frequency’s efforts now will focus on continuing to develop novel therapeutics to induce remyelination for individuals living with MS. The Company previously reported that it had identified a ...

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function ...

(2023-07-14) Korro Bio and Frequency Therapeutics Announce Merger Agreement (2023-07-14) Korro Bio and Frequency Therapeutics Announce Merger Agreement Stockhouse.com uses cookies on this site. By ...